Ross Youngs: ‘We investigate the aquatic microbiome to obtain metabolites and postbiotics’

New technologies such as the analysis of the "aquatic microbiota" allow to dig deeply into the microbiome chemistry. We discuss this approach with Ross Youngs, CEO of Biosortia.

New technologies allow researchers to investigate more and more deeply into the chemistry of the human microbiome and to obtain new compounds suitable for pharmaceutical use.

A new opportunity comes from the analysis of the so called “aquatic microbiota“: a method based on the growth of non-culturable microorganisms in the aquatic environment that allows to track down and recover traces of secondary metabolites.

According to Ross Youngs, CEO and founder of Biosortia Pharmaceuticals, a startup that is developing this method, the new approach will make thousands of currently unknown chemicals available. “We have already demonstrated – explains Youngs – the therapeutic feasibility of this approach through which we’ve been able to find immune system modulators. Biosortia is tapping a source that has never been tapped before».